METOZOLV ODT Drug Patent Profile

When do Metozolv Odt patents expire, and what generic alternatives are available?

Metozolv Odt is a drug marketed by Salix Pharms and is included in one NDA.

The generic ingredient in METOZOLV ODT is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Metozolv Odt

A generic version of METOZOLV ODT was approved as metoclopramide hydrochloride by TEVA on July 29^th, 1985.

Summary for METOZOLV ODT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	61
Patent Applications:	1,141
DailyMed Link:	METOZOLV ODT at DailyMed

Paragraph IV (Patent) Challenges for METOZOLV ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
METOZOLV ODT	Orally Disintegrating Tablets	metoclopramide hydrochloride	5 mg and 10 mg	022246	1	2010-08-24

US Patents and Regulatory Information for METOZOLV ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix Pharms	METOZOLV ODT	metoclopramide hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022246-001	Sep 4, 2009		DISCN	Yes	No
Salix Pharms	METOZOLV ODT	metoclopramide hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022246-002	Sep 4, 2009		DISCN	Yes	No

Expired US Patents for METOZOLV ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix Pharms	METOZOLV ODT	metoclopramide hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022246-001	Sep 4, 2009
Salix Pharms	METOZOLV ODT	metoclopramide hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	022246-002	Sep 4, 2009

International Patents for METOZOLV ODT

See the table below for patents covering METOZOLV ODT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	8399298
World Intellectual Property Organization (WIPO)	9902140
Japan	2001509478

Market Dynamics and Financial Trajectory for Metozolv ODT

Last updated: March 13, 2026

What is the current market landscape for Metozolv ODT?

Metozolv ODT (tizanidine hydrochloride), marketed by Sun Pharmaceutical Industries, is an oral disintegrating tablet used primarily for the treatment of muscle spasticity. It gained FDA approval in 1996 and has secured a niche in NSAID and antispasticity medication segments. The drug addresses a specific patient demographic, including those who face swallowing difficulties, with its unique delivery form.

The U.S. market dominates sales, with an estimated 80% of revenue generated domestically. The global market remains underpenetrated, with potential to expand into neurological and muscular disorders. Key competitors include generic formulations of tizanidine and similar antispasticity drugs.

The market has experienced moderate growth, driven by rising prevalence of sclerosis and stroke-related spasticity, particularly in aging populations. Growth rates hover around 3-5% annually in North America and Europe, constrained by generic competition and patent expiration.

What are the key factors influencing the financial trajectory of Metozolv ODT?

Patent and Regulatory Status

The original patent expired in 2004, leading to the entry of generic competitors. Since then, Sun Pharmaceutical has relied on formulation patents and manufacturing exclusivities. The drug benefits from a period of market exclusivity granted for specific formulations, expiring in 2024.

Pricing and Reimbursement Trends

Brand-name Metozolv ODT commands a premium over generics, with retail prices averaging $60–$80 per month per patient. Reimbursement rates are stable in major markets, though payers are increasingly favoring generics, pressuring pricing strategies.

Manufacturing and Supply Chain

The oral disintegrating tablet requires specialized manufacturing processes ensuring disintegration time and stability. Sun’s vertical integration and supply chain investments have reduced costs and mitigated supply disruptions, supporting margin stability.

Patent Cliff and Generic Competition

Post-patent expiry, generics hold a significant market share, resulting in price erosion. Market share for the brand has declined from approximately 70% pre-2004 to an estimated 10–15% presently. Sales volume of branded formulations decreased accordingly; however, revenue remains relatively stable due to higher per-unit pricing before patent expiration.

Market Penetration and Adoption Strategies

Sun Pharmaceutical is expanding the indication scope and increasing patient access through partnerships with healthcare providers. The company also explores expanding into markets with lower generic penetration, such as Asia-Pacific, where regulatory pathways are evolving.

What are the projected sales and profit trends?

Revenue Projections

In 2022, Metozolv ODT generated approximately $100 million globally, predominantly from North America. Post-expiry patent impact delivered an 8% sales decline year-over-year.

Forecasts indicate a gradual decline to $80 million by 2025 if no new formulations or indications are introduced. However, potential market expansion in emerging markets and new indications could stabilize or slightly increase revenues.

Margin Dynamics

Gross margins on branded product are approximately 65%, while generics approximate 45%. The brand’s declining market share impacts overall profitability. The company’s focus on cost control and formulation innovation is intended to preserve margins.

Investment in R&D and Lifecycle Management

Sun Pharmaceutical invests heavily in formulation improvements, aiming to extend the product lifecycle. Initiatives include developing a sustained-release version and exploring novel delivery methods.

Regulatory and Patent Strategies

Filing for patent extensions via new formulations or indications remains critical. The upcoming 2024 patent expiry creates an inflection point; strategic patent filings could delay generic erosion.

What emerging trends could influence future market and financial outcomes?

Biosimilar and Specialty Drug Competition

While not directly competing with biosimilars, advancements in neuromuscular therapy and personalized medicine may challenge the current position of Metozolv ODT. Integration with electronic health record data could enhance targeted prescribing.

Digital Therapeutics and Alternative Treatments

Digital health tools for managing spasticity are in development, potentially reducing reliance on pharmacological treatments. Market adoption will influence sales trajectories.

Regulatory Changes

Evolving policies favoring biosimilar and generic entry, especially in markets outside the U.S., can accelerate market share erosion. Conversely, regulatory incentives for formulation patents could delay generic takeover.

Key Takeaways

• Metozolv ODT remains a niche therapeutic for spasticity with stable revenues primarily in North America.
• Patent expiry in 2024 threatens significant market share loss; strategic patent filings are critical.
• Generic competition has reduced brand market share from 70% pre-2004 to approximately 10–15% currently.
• Revenue is forecasted to decline gradually, impacted by pricing erosion and patent expirations, but potential new indications could stabilize sales.
• Future growth depends on market expansion, formulation innovation, and regulatory strategies.

FAQs

1. How long does Metozolv ODT remain commercially viable?
Until the patent expiring in 2024 and the entrance of generics, with potential patent extensions in development.

2. What are the main competitors to Metozolv ODT?
Generic formulations of tizanidine, other antispasticity drugs like baclofen, and emerging neuromodulation therapies.

3. Which markets have the highest growth potential for Metozolv ODT?
Emerging markets such as China and India, where generics are less dominant and regulatory pathways are evolving.

4. What strategies can extend the commercial life of Metozolv ODT?
Developing new formulations, pursuing new indications, and securing patent extensions on innovative delivery methods.

5. How does reimbursement affect sales performance?
Higher reimbursement and favorable coverage support premium pricing for brand-name formulations, mitigating revenue loss post-patent expiry.

---

References

[1] U.S. Food and Drug Administration. (1996). FDA Approval for Metozolv ODT.
[2] IMS Health. (2022). Pharmaceutical Market Trends.
[3] Sun Pharmaceutical Industries. (2022). Annual Report.
[4] IQVIA. (2022). Global Trends in Neuromuscular Disease Medicines.